Beta Bionics Rises 2.2% After FDA Clears Mint Patch Pump

Beta Bionics Inc shares rose 2.2% on Monday following regulatory clearance from the U.S. Food and Drug Administration for its Mint patch pump. The medical device manufacturer advanced in trading despite concurrent downward revisions to its full-year revenue guidance stemming from projected customer deferrals ahead of the product launch.

Following the regulatory announcement, Beta Bionics (BBNX) traded at $22.18, up 15.34% from its previous close of $19.23 as of September 16, 2026, according to Finnhub market data.

Revenue Guidance and Launch Timeline

Alongside the FDA clearance announcement, the company adjusted its financial projections for the upcoming quarters. Beta Bionics revised its full-year 2026 revenue guidance to a range of $121 million to $126 million, down from its earlier forecast of $131 million to $136 million.

According to company reports, the reduction accounts for a potential revenue deferral impact of up to $10 million in the fourth quarter of 2026. This dip is anticipated as prospective users of the existing iLet system temporarily delay purchases to wait for the Mint pump rollout.

Full U.S. commercialization of the Mint patch pump is scheduled to begin in the first quarter of 2027, giving the enterprise several months of transition between its established flagship offerings and the new hardware line.

Understanding Patch Pumps in Diabetes Care

Patch pumps represent a distinct category in insulin delivery technology, differing from traditional tubed insulin pumps through a direct-to-skin adhesive design that eliminates infusion sets and external tubing. These devices aim to reduce physical snags and offer discretion for patients managing Type 1 and Type 2 diabetes.

The regulatory clearance of the Mint device expands Beta Bionics' footprint in the automated insulin delivery sector, where companies compete to integrate continuous glucose monitors with adaptive dosing algorithms. Regulatory approvals in this space typically require extensive clinical evaluation of delivery accuracy and occlusion detection mechanisms to ensure patient safety against insulin under-delivery or over-delivery.

What Is at Stake for Market Position

The introduction of the Mint patch pump positions Beta Bionics to capture additional market share in the competitive ambulatory infusion pump industry. However, the anticipated fourth-quarter sales deferrals underscore the adoption friction medical device makers face when announcing next-generation hardware ahead of its physical availability in clinical settings.